Distinct glucose‐lowering properties in good responders treated with sitagliptin and alogliptin

Publisher： John Wiley & Sons Inc

E-ISSN： 1742-1241|69|11|1296-1302

ISSN： 1368-5031

Source： INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol.69, Iss.11, 2015-11, pp. : 1296-1302

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus

By Jung Jin   Kaku Kohei   Kim Jae   Kim Jung-Ryul   Ko Jae-Wook   Lee Soo-Youn   Huh Wooseong  

Advances in Therapy, Vol. 30, Iss. 11, 2013-11 ,pp. : 1018-1029

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenetics of Glucose-Lowering Drug Treatment: A Systematic Review

By Bozkurt Özlem  

Molecular Diagnosis & Therapy, Vol. 11, Iss. 5, 2007-01 ,pp. : 291-302

Adis International

Access to resources Recommend Favorite

Glucose‐Lowering Effect of Sevelamer Hydrochloride in Hemodialysis Patients

By  

THERAPEUTIC APHERESIS AND DIALYSIS, Vol. 19, Iss. 4, 2015-08 ,pp. : 412-413

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sevelamer in a diabetologist's perspective: a phosphate‐binding resin with glucose‐lowering potential

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 2, 2015-02 ,pp. : 116-120

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment

By Penning-van Beest Fernie J. A.   van der Bij Sjoukje   Erkens Joëlle A.   Kessabi Sophia   Groot Martijn   Herings Ron M. C.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2523-2529

Informa Healthcare

Access to resources Recommend Favorite